Big shout out to Håvard Midgard and colleagues from Oslo on their work to reach people with recent injecting drug use at #ILC2019 - Treatment uptske 65% so far half of untested LTFU C-frit syd / C-free south

Håvard Midgard How can we achieve WHO's elimination target for hepatitis C incidence? thelancet.com/journals/langa…

At #INHSU2021 session #Innovations in HepC Testing and Treatment Håvard Midgard presented live #peer #mobile #HCVclinic.

Practice changing findings ALERT: from OPPORTUNI-C in Norway, a pragmatic RCT showing inpatient initiation of HCV rx is doable, safe, and WORKS...even in a pandemic. A tour de force from Håvard Midgard Ane-Kristine SELIHEP at #INHSU2022

Take home message from Kristian Malme today INHSU: Although HCV treatment uptake increased among people who inject drugs in 🇳🇴, strategies to improve treatment among women and individuals not engaged in OAT should be addressed!

Last session INHSU and grateful that the main result from Opportuni-C was highlighted in Tommy Brothers rapporteur! Håvard Midgard

What a concept! Starting treatment for people with chronic but curable infections in the hospital. Too bad most insurers and Medicare.gov won’t cover such out-patient issues.

Don’t put off until tomorrow what you can do today: Hospital admissions as an opportunity to treat hepatitis C ✅ Just Accepted 💬 Editorial Commentary 🔗 bit.ly/47nNWip

Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): A stepped wedge cluster randomized trial academic.oup.com/cid/article/do…

Remarkable RCT from Norway demonstrating that starting HCV treatment in the hospital with newly diagnosed HCV among PWIDs is superior to deferring therapy to outpatient care in achieving HCV cure. Results argue for broader use. Håvard Midgard SELIHEP doi.org/10.1093/cid/ci…

Inspiring work by inspiring people Ane-Kristine Håvard Midgard SELIHEP - It's time to stop writing "hcv, defer to outpatient" in your consult notes, #idtwitter

Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): A stepped wedge cluster randomized trial ✅ Just Accepted 🔓 Open Access 🔗 bit.ly/40YwC17 via Håvard Midgard SELIHEP

New: Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial - thelancet.com/journals/langa… #hepC #nohep #harmreduction Jason Grebely

Scale-up of #HCV #treatment and other interventions is needed to minimise #hepatitisC transmission in #PWID in #Europe bit.ly/2zQRBWR #openaccess #hepc #Hepatitis EASL Advocacy

Very proud to see my mentor, collaborator, and friend @GregDore2 Kirby Institute, UNSW recognised by The Lancet Gastroenterology & Hepatology for his leadership in advancing #HCV therapeutics, care for #PWID and elimination efforts - Congrats and well-deserved! thelancet.com/journals/langa…

Opponent in interesting PhD defense in Oslo today. Congratulations to Håvard Midgard olav Dalgard

He did a great job. Thank you Jason Grebely Martin Kåberg for the video greetings. His work will be the foundations for NO #hepc strategy x.com/oevrehusdk/sta…

#EASLmono conf on elimination of #hepatitisC infection was a great success, watch the webcasts & ePosters on #EASL #LiverTree bit.ly/2oiN8ay #HCV #publichealth #testing #treatment #epidemiology EASLnews Jeffrey V. Lazarus JM Pawlotsky Ahmed Elsharkawy Alessio Aghemo

«The times they are a’changin’» – Positioning EASLnews in the changing landscape of hepatology bit.ly/2oxZyw0 Tom Hemming Karlsen

We World Health Organization (WHO) just released a new report on #hepatitis C treatment. It shows the annual number of people initiating HCV curative treatment increased from 1 mln in 2015 to 1.5 mln in 2016. But access is focused primarily in a few high-burden countries. bit.ly/2IflsfU #NOHEP